CN102579817A - Chinese medicine composition with function of treating osteoporosis - Google Patents
Chinese medicine composition with function of treating osteoporosis Download PDFInfo
- Publication number
- CN102579817A CN102579817A CN201210079204XA CN201210079204A CN102579817A CN 102579817 A CN102579817 A CN 102579817A CN 201210079204X A CN201210079204X A CN 201210079204XA CN 201210079204 A CN201210079204 A CN 201210079204A CN 102579817 A CN102579817 A CN 102579817A
- Authority
- CN
- China
- Prior art keywords
- chinese medicine
- bone
- medicine composition
- herba epimedii
- rhizoma
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a Chinese medicine composition with a function of treating osteoporosis, which is composed of fructus psoraleae, herba epimedii, rhizoma polygonati, drynaria rhizome, fructus lycii, achyranthes root and the like. The Chinese medicine composition with the function of treating osteoporosis is good in curative effect and low in side effect and has the function of remarkably increasing bone mineral density.
Description
Technical field
The invention belongs to field of medicaments, be specifically related to a kind of osteoporotic Chinese medicine composition that is used to treat, also relate to its preparation and method for preparing
Background technology
Sclerotin sulfur pine disease is a kind of commonly encountered diseases that threatens the senior health and fitness, reduces with the bone amount, and osseous tissue microstructure change and risk of fractures degree increase to characteristic.The osteoporosis sickness rate is very high, and the senile osteoporosis sickness rate is about 59.87% more than 60 years old, and the sickness rate of middle and aged women is then higher, and the morbidity ratio can reach 6 between the men and women: 1-2: 1.Total bone loss annual after women's menolipsis is approximately about 2.2-3%, and the vertebral body center reaches 6-8%, the women after menopause to about 70 years old during this period of time in always bone loss can reach 20-30%.
(1) definition of osteoporosis
The initial notion of osteoporosis is that Pommer put forward in 1885; But never have clear and definite definition; Early stage people it is generally acknowledged that the whole body osteopenia is osteoporosis; In the 4th the international osteoporosis seminar of holding in Hong Kong in 1993; Osteoporosis has just had clear and definite definition, and obtains international generally acknowledging: primary osteoporosis deteriorates to characteristic with the minimizing of bone amount, osseous tissue microstructure, causes a kind of general skeletal diseases that fragility increases and the risk of fractures degree increases of bone.Specific targets are following:
1. the bone amount reduces, and should comprise the minimizing of bone mineral and bone matrix ratio.Have only the minimizing of bone mineral, and bone matrix not reducing, is due to the bone mineralising obstacle, make that the interior mineral of unit volume is undesired with organic ratio, and the total amount of bone is constant.Clinical manifestation is an osteomalacia concerning the adult, and is then sick for arresting the building concerning the child.The category that does not belong to osteoporosis.
2. the microstructure of bone is degenerated, mainly by due to the bone resorption, mainly show as bone trabecula attenuate, thinning, and even fracture.We can think that this is a kind of little fracture, can cause the whole body skeleton pain.
3. the intensity decreases of bone, fragility increases, and is difficult to bear original load.Compression fracture of lumbar vertebra can take place suddenly, or wrist distal radius fracture or lofty and unyielding character fractured near end just can take place under little external force.
4. can find the variation of morphosis in the osseous tissue and bone amount in X skiagram, light microscopic pathology sheet, Electronic Speculum microphotograph.
5. the bone amount reduces, and bone calcium is lost and made spinal column be prone to compression fracture takes place, and causes bow-backed appearance.
6. the bone amount reduces and structure degradation, and the reflection bone density descends, and can adopt ray or ultrasound examination to come out.
(2) classification of osteoporosis and typing
1. the classification of osteoporosis
Osteoporosis can be divided into three major types substantially, and the first kind is a primary osteoporosis, and it is a kind of physiological degeneration that must take place with age.
Second type is secondary osteoporosis; It is the osteoporosis of being brought out by factors such as other diseases or medicines, can cause osteoporosis like life-time service adrenal cortex parahormone, and main cause possibly promote glyconeogenesis with corticoid; Protein is decomposed to be increased; Biosynthesis block is relevant, causes the organic matter of bone to form minimizing, and the osteoblast activity is suppressed.Corticoid can also suppress the absorption of small intestinal calcium in addition, causes negative calcium balance, influences sclerotin and forms, and causes bone resorption to increase.During hyperthyroidism, osteoblast and osteoclast activity increase, and the collagen tissue of bone is destroyed and increased; The formation of sclerotin and absorption, metabolism and renewal all increase; The conversion ratio of bone calcium increases, and the excretion of urine calcium also increases, thereby the Secondary cases that produces bone is loose.Fracture, osteopathia, arthritis or long-term bed due to illness, thus stiff, bear a heavy burden, the mechanical stimulus of skeleton is weakened, not only the muscle disease contracts, and the bone formation effect reduces, bone absorption increases relatively, forms osteoporosis.Malnutrition can cause serious potein deficiency, causes the organic matter generation of bone bad, causes osteoporosis indirectly.
The 3rd type is idiopathic osteoporosis disease, is mainly in 8-14 year teenager, and the women is more than the male.The osteoporosis that takes place women's gestation and age of sucking also can be listed idiopathic osteoporosis in.
2. the typing of osteoporosis
Primary osteoporosis can be divided into two types, and the I type is a postmenopausal osteoporosis, is high conversion type osteoporosis.The II type is a senile osteoporosis, for low conversion type osteoporosis, mainly occurs in the old people more than 50 years old.
The difference of the two is that mainly the speed of bone loss is different, I type bone loss faster, and mass loss rates is not accelerated in the II type bone.The M-F of I type is approximately 6: 1, and the M-F of II type is approximately 2: 1, and women's ratio generally is higher than the male.
The theory of propositions such as Ego thinks that the difference of osteoporosis is the mode difference that bone is rebuild between both sexes, and the women is main with the bone resorption enhancing, and the male is reduced to the master with bone formation.
(3) treatment of osteoporosis
1. common method of treatment
Also not having ideal especially medicine fundamentally to cure both at home and abroad at present should disease.
The normal therapeutic scheme that adopts of doctor trained in Western medicine has:
A. controversies in hormone replacement in the elderly is primarily aimed at the postmenopause women, can effectively alleviate bone loss, common drug such as diethylstilbestrol, estradiol etc. after the menopause.
B. replenish calcium preparation and vitamin D commonly used calcium lactate, calcium gluconate etc. are arranged
C. Diphosphonate such as alendronate etc. can suppress bone resorption, reduce bone loss, and good analgesic effect is arranged, and clinical efficacy is better.
D. calcitonin can reduce bone resorption, mainly is applicable to high conversion type sufferers of osteoporosis face.
Sodium fluoride also has the effect of tangible increase bone amount in addition, but because it can not reduce risk of fractures, does not therefore advocate independent use.
The Chinese medicine therapy
Traditional Chinese medical theory thinks that the kidney being the origin of congenital constitution, Source of life, and kidney storing essence, main bone is given birth to marrow, and deficiency of kidney-essence is difficult nourishing bone then can cause withered bone with deficient medulla, and passages through which vital energy circulates loses supports, and occurs that waist is cold aches, the symptom of brothers' joint stuffiness.Therefore we can think and suffer from a deficiency of the kidney and osteoporosis has substantial connection.
" element is asked. declare five gas opinion ": " visceral controllings, kidney governing bones." " element is asked. six joint state of internal organs pieces of writing ": " kidney governing bones marrow ", kidney essense is sufficient, and then bone marrow biochemistry is active, and bone must nourish and firm strong.Chinese medicine is listed osteoporosis in the category of suffer from a deficiency of the kidney " rheumatism involving the bone "." rheumatism involving the bone " mainly due to suffering from a deficiency of the kidney, deficiency of kidney-essence can not be given birth to marrow, and with the passing of time bone loses due to the nutrition.
Chinese medicine is guidance with traditional determination of treatment based on pathogenesis obtained through differentiation of symptoms and signs, integrally-regulated theory, on osteoporotic clinical treatment, makes remarkable progress.Clinical common pattern of syndrome has deficiency of the kidney yin, insufficiency of kidney-YANG, stagnation of liver-QI with deficiency of the spleen, stagnation of QI blood stagnation etc.Corresponding medicine is main with warming and recuperating the kidney-YANG, nourishing kidney yin, spleen invigorating tonify deficiency, promoting blood circulation to remove obstruction in the collateral also.Like Cornu Cervi Pantotrichum, excessive sheep flower bud, Radix Rehmanniae Preparata, Carapax Et Plastrum Testudinis, the Radix Astragali, Radix Ginseng, Flos Carthami etc.
Modern pharmacology proves that osteoporosis Chinese medicine has pharmacological action widely, as improving sex hormone level; Regulate the alcium and phosphor metabolization balance; Influence the osteoblast osteoclast activity, delay the aging of gonadal tissues such as ovary, uterus, emerald green ball, thereby function of resisting osteoporosis is preferably arranged.
Chinese patent CN 03117641.0 discloses osteoporotic Chinese medicine preparation of a kind of treatment and preparation method thereof.Be made up of Concha Ostreae powder, Herba Epimedii, Rhizoma Chuanxiong, triangular, Radix Dipsaci, the Rhizoma Anemarrhenae, Radix Rehmanniae and Radix Paeoniae Rubra, its adopts the method for water extraction, processes powder, fracture, osteodynia, osteoarthritis that osteoporosis is caused, and prevention climacteric osteoporosis has better effects.
Chinese patent CN 200710148683.5 provides osteoporotic Chinese medicine preparation of a kind of treatment and method for preparing.By weight by: Fructus Psoraleae 12～48, Herba Epimedii 12～48, Radix Rehmanniae Preparata 18～48, Radix Salviae Miltiorrhizae 12～48 and Concha Ostreae 5～58 are formed, through ethanol extraction, hot water extraction, pulverizing, the sheet that makes, capsule, ball, granule.Have tangible invigorating the kidney and strengthening the bones effect, osteoporosis is had tangible preventive and therapeutic effect.
Chinese patent CN 201110131662.9 discloses the osteoporotic compound preparation of a kind of treatment; It is to be processed by following materials of weight proportions: Flos Carthami 5-50, Radix Notoginseng 30-120, Radix Astragali 6-60, Radix Ginseng 10-100, Cortex Eucommiae 10-80, Pericarpium Citri Reticulatae 5-50; Dosage form is capsule, patch, granule, spray, tablet, pill, mixture etc.; Has the obvious effect that improves blood circulation and microcirculation, tonifying liver, the kidney invigorating, activating blood circulation and supplementing qi; Obvious to treatment osteoporosis effect, and safe and reliable continuously.
Summary of the invention
To the deficiency of present existence, the invention provides a kind of osteoporotic Chinese medicine composition that is used to treat.Have good effect, side effect is low, significantly the effect of bone density improving.
The Chinese drug-treated group of Chinese medicine composition of the present invention becomes:
Fructus Psoraleae 240-600 Herba Epimedii 210-580 Rhizoma Polygonati 210-580 Rhizoma Drynariae 210-580
Fructus Lycii 180-500 Radix Achyranthis Bidentatae 180-500
Preferably, the Chinese medicine of Chinese medicine composition of the present invention composition weight part ratio example is:
Fructus Psoraleae 300-500 Herba Epimedii 280-450 Rhizoma Polygonati 260-480 Rhizoma Drynariae 250-460
Fructus Lycii 220-420 Radix Achyranthis Bidentatae 240-400
Further preferred, the Chinese medicine of Chinese medicine composition of the present invention is formed the weight part ratio example and is:
Fructus Psoraleae 400 Herba Epimedii 350 Rhizoma Polygonatis 350 Rhizoma Drynariae 350
Fructus Lycii 300 Radix Achyranthis Bidentataes 300
Herba Epimedii is the dry aerial parts of Berberidaceae plant Herba Epimedii Epimedium brevicornumMaxim., arrow leaf Herba Epimedii Epimedium sagittatum (Sieb.et Zucc.) Maxim., pubescence Herba Epimedii Epimedium pubescens Maxim., the excessive sheep work Epimedium wushanense T.S.Ying in Wushan or Herba Epimedii Epimedium koreanum Nabai.Tapped when summer, autumn, stem and leaf was luxuriant, remove thick stalk and impurity, dry or dry in the shade.Nature and flavor are hot, sweet, temperature.Return liver, kidney channel.Be traditional kidney-nourishing tcm drug, have the effect of kidney-replenishing, bone and muscle strengthening.Herba Epimedii has " kidney-replenishing, bone and muscle strengthening, wind-damp dispelling " in the version Pharmacopoeias of the People's Republic of China in 2005.The effect that Li Shizhen (1518-1593 A.D.) is claimed it in Compendium of Material Medica have " beneficial vital essence, hard muscles and bones are mended the waist knee joint, heart tonifying power ".Modern pharmacological research shows that Herba Epimedii has multiple pharmacodynamic feature, mainly concentrates on immunity, reproductive system, nucleic acid metabolism, cardio-cerebrovascular and the anti-ageing aspect of waiting for a long time.Research shows that Herba Epimedii total flavones has certain preventive and therapeutic effect to osteoporosis.Extracing the ovary method like usefulness such as Ji Hui combines low calcium feedstuff to set up the osteoporosis rat model; With Herba Epimedii total flavones successive administration 3 months in 75～300mg/kg dosage range; Compare with the model group rat; Can obviously improve apparent surface density of rat femur and bone density and do not raise uterus index and serum estradiol level, and the trend that improves bone calcium, bone phosphorus is arranged.Li Qingnan etc. have observed Herba Epimedii water extract to going the metabolic influence of testis rat bone; Find that water extract can partly suppress the bone high-conversion rate of testis rat and not reduce the bone mineralising; Can be enhanced to bone cell function, rats with osteoporosis due to the glucocorticoid is also had certain therapeutic effect.The rats with osteoporosis that preliminary proof such as Bao Jiarong icariin causes removal ovary has curative effect preferably, discloses it and in prevention of osteoporosis or treatment, works.
Fructus Psoraleae is the dry mature fruit of legumes psoraleae Psoralea corylifolia L..The infructescence of gathering during fruit maturation autumn is dried, and rubs fruit, removes impurity.The traditional Chinese medical science is thought: Fructus Psoraleae is the kidney invigorating and YANG supporting medicine, its acrid in the mouth, hardship, and temperature is returned kidney, spleen channel, and can wet spleen antidiarrheal, warming and recuperating the kidney-YANG can reach the function of mending bone through invigorating the kidney and spleen.Modern pharmacological research shows that Fructus Psoraleae has multiple pharmacologically active, mainly concentrates on aspects such as mending bone, raise immunity, antibacterial, antiviral, antitumor.In vitro tests shows, Fructus Psoraleae can suppress to separate the increase and the expansion of the absorption lacuna that osteoclast forms on osteocomma, thereby shows that it has inhibitory action to separating osteoclast.The nonpolar part of Fructus Psoraleae acetone extract can increase rat bone intensity, improves inorganic phosphate salt level in the blood, confirms that through analyzing its action component is a Fructus Psoraleae oils and fats portion.Suspension with Chinese medicine of the five flavours such as Fructus Psoraleae, Radix Achyranthis Bidentatae, Fructus Lycii are made into is given rat oral gavage; Observe its influence to osteoporosis rat model due to the retinoic acid; This suspendible fluid power makes the rat model serum alkaline phosphatase reduce to normal level; Significantly reduce Ca/Cr and HOP/Cr level in the urine, and significantly suppress bone resorption, make the rat bone metabolism be in the poised state of bone formation greater than bone resorption
[17]Two medicines share, invigorating the liver and kidney altogether, the merit of bone and muscle strengthening.
Rhizoma Polygonati is the dry rhizome of liliaceous plant Yunnan Rhizoma Polygonati Polygonatum kingianumColl.et Hemsl., Rhizoma Polygonati Polygonatum sibiricum Red. or Polygonatum cyrtonema Hua Polygonatum cyrtonema Hua.Its nature and flavor are sweet, and are flat, return spleen, lung, kidney channel.Beginning is stated from " bright doctor does not record ".Li Shizhen (1518-1593 A.D.) is said: " Rhizoma Polygonati is for taking key medicine ".Another name embodies its medicine-food two-purpose property for " celestial being's surplus grain ", " JIUMINGCAO ", " Rhizoma Polygonati Cirrhifolii " etc." the Qingyang county annals " of the Shennong's Herbal of Han dynasty, the Compendium of Material Medica of the Ming Dynasty and the Qing Dynasty also all have its record as medicated diet tonic effect.Rhizoma Polygonati has the alleviating distention in middle-JIAO QI invigorating as a kind of traditional rare Chinese medicine, enriching kidney essence, nourishing YIN and moistening the lung, the effect of the spleen reinforcing of promoting the production of body fluid.Modern pharmacological research Rhizoma Polygonati main pharmacodynamics function concentrates on blood sugar regulation, antitumor, antibacterial, antiinflammatory, antiviral, adjusting immunity, improves effects such as learning and memory, resisting fatigue, slow down aging.Chen Songcang etc. are with Rhizoma Polygonati oral liquid 0.2; 0.4ml/d 4 weeks of continuous irrigation stomach mice (making the positive, negative control respectively with Oral Liquid Radix Panacis Quinquefolii and water respectively); Put to death behind the swimming 90min; This oral fluid power of result significantly reduces the heart, liver lipid peroxide (LPO) generates, and increases glutathione peroxidase activity and blood superoxide dismutase (SOD) vigor.Xia Xiaokai etc. have studied the antioxidation in vitro effect of polygonatum polysaccharide; The result shows that it can suppress spontaneous and generation inductive lipid peroxidation product malonaldehyde (MDA) external; Oxygen-derived free radicals is had direct scavenging action, show polygonatum polysaccharide antioxidation and anti-aging aspect have certain effect.
Rhizoma Drynariae is the dry rhizome of Polypodiaceae plant Mongolian oak Herba pteridii latiusculi Drynaria fortunei (Kunze) J.Sm..All can excavate the whole year, removes silt, drying. or burn remove floss (scale) again.Its nature and flavor are bitter, and temperature is returned kidney, Liver Channel.Beginning is stated from supplement to the Herbal, is the successive dynasties conventional Chinese medicine, has the kidney invigorating bone strengthening, continues effects such as hindering pain relieving.Modern pharmacological research shows that Rhizoma Drynariae has multiple pharmacodynamic feature, mainly concentrates on aspects such as tonifying liver and kidney and strengthening bones and muscles, blood fat reducing, analgesia, calmness.The Rhizoma Drynariae extracting solution has inhibitory action to in-vitro separation osteoclast property bone resorption, increases inhibitory action more obviously with concentration.With the fracture model of rat, the influence that the research Rhizoma Drynariae is expressed TGF-β in the fracture healing process 1.The result shows: the osteomiosis complementary energy increases callus thickness, improves the union of fracture quality, increases the expression of TGF-β 1 in the callus tissue.Experimental results such as Liu Jian is firm show the effect that the Rhizoma Drynariae total flavones has increases rat bone density, and can improve the calcium level of animal.The curative effect of Rhizoma Drynariae total flavones to the sufferers of osteoporosis face osteodynia found in king and ring etc., total effective rate 94.44%, cure-remarkable-effectiveness rate 70.99%, to average onset time of osteodynia be 4.94 ± 2.26 weeks, the uniform release time was 7.47 ± 2.81 weeks, treated safe and effective.
Radix Achyranthis Bidentatae is the dry root of amaranthaceous plant Radix Achyranthis Bidentatae Achyranthes bidentata Bl..Excavate when stem and leaf is withered winter, removes fibrous root and silt, ties into wisp, shines as for after the wrinkle, and the top is trimmed, and dries.Beginning is stated from Shennong's Herbal, classifies as top grade.Its nature and flavor are bitter, sour, and are flat, return liver, kidney channel.Invigorating the liver and kidney is arranged, bone and muscle strengthening, eliminating blood stasis and inducing menstruation, the effect of conducting blood to flow downwards.Modern pharmacological research shows that Radix Achyranthis Bidentatae has significant anti-aging effects and human body immunity improving function, and expansible animal lower limb vascular improves hemorheology index, with ancients the argumentation of its invigorating the liver and kidney, bone and muscle strengthening, blood circulation promoting and blood stasis dispelling is matched; Contain more rich zinc in the Radix Achyranthis Bidentatae, trace element such as volume potassium, ferrum, copper, and ecdysterone, inokosterone.Ecdysterone can improve liver function in the Radix Achyranthis Bidentatae, reduces plasma cholesterol, and the protein synthesis facilitation that the ecdyson tool is stronger can significantly improve the function of aminoacid synthetic protein, reaches invigorating the liver and kidney, strengthening bone and muscle, antidotal effect.Find that in the research of Cui Hongying the benefit bone Chinese drug-treated group that contains Radix Achyranthis Bidentatae can alleviate rat uterus weight, increase bone trabecula density, area, cumulative volume and Compact bone area, reduce the medullary cavity area.
Fructus Lycii is the dry mature fruit of plant of Solanaceae lycium barbarum Lycium barbarum L..Summer, autumn gathered when two seasons, fruit took on a red color, and hot-air seasoning is removed carpopodium, or dried in the air to rhicnosis, dried, and removed carpopodium.Beginning is stated from Shennong's Herbal and is classified as top gradely, calls it: " obey hard muscles and bones for a long time, it is not old to make light of one's life by commiting suicide, cold-resistant summer-heat ", its nature and flavor are sweet, and are flat, return liver, kidney channel.Nourishing the liver and kidney is arranged, the effect of replenishing vital essence to improve eyesight.Modern pharmacological research thinks that Fructus Lycii contains chemical constituents such as LBP, riboflavin, betanin, carotene, thiamine.To human body have antioxidation, defying age, antitumor, blood fat reducing, protect the liver, effect such as AFL, blood sugar lowering.
Prescription is mainly according to theory of Chinese medical science, and with reference to the modern pharmacology research data.We are to be guidance with the theory of Chinese medical science, the effective proved recipe that from long-term clinical practice, sums up, and this side's determined curative effect, rapid-action, no toxicity has the good curing effect to osteoporosis.Theory of Chinese medical science thinks that kidney storing essence master bone is given birth to marrow, and deficiency of kidney-essence is the main cause that osteoporosis (bone withers) takes place.Fructus Psoraleae, Herba Epimedii ability warming and recuperating the kidney-YANG in the side, the effect of bone and muscle strengthening, and Rhizoma Polygonati has tonifying kidney-yin, the effect of spleen invigorating.Blood stored in the liver, kidney storing essence, essence and blood alternate, yi and Kui are derived from the same origin.The nourishing depend on liver blood is contained in filling of essence in kidney, and liver blood foot then kidney essense fills and bone is strong.Rhizoma Drynariae, Fructus Lycii, Radix Achyranthis Bidentatae then have good invigorating the liver and kidney, the bone and muscle strengthening effect.All medicines share, and seven emotions are harmonious between the medicine, play invigorating the liver and kidney altogether, and the merit of bone and muscle strengthening is to the osteoporosis effect of having clear improvement.
Chinese medicine composition of the present invention can be called clinical acceptable various dosage forms through the preparation process preparation of routine, as: clinical dosage forms commonly used such as granule, tablet, pill, capsule.
The preferred dosage form of Chinese medicine composition of the present invention is a capsule.
The preparation technology of Chinese medicine composition of the present invention is:
Get the Chinese crude drug in the Chinese medicine composition of the present invention, measure Fructus Psoraleae, Herba Epimedii, Rhizoma Polygonati, Rhizoma Drynariae, Fructus Lycii and Radix Achyranthis Bidentatae Six-element medical material, add 8-12 times of water gaging respectively and decoct, decoct 2-4 time, each 0.5-3 hour according to above-mentioned prescription; Merging filtrate, being concentrated into density is the extractum of 0.8-2.0 (60 ℃ of surveys), it is dry that extractum adds calcium lactate, becomes clinical common formulations according to the common dosage forms prepared.
The preparation technology of Chinese medicine composition of the present invention is:
Get the Chinese crude drug in the Chinese medicine composition of the present invention, measure Fructus Psoraleae, Herba Epimedii, Rhizoma Polygonati, Rhizoma Drynariae, Fructus Lycii and Radix Achyranthis Bidentatae Six-element medical material, add 8-12 times of water gaging respectively and decoct, decoct 2-4 time, each 0.5-2 hour according to above-mentioned prescription; Merging filtrate, being concentrated into density is the extractum of 1.0-1.7 (60 ℃ of surveys), it is dry that extractum adds calcium lactate, becomes clinical common formulations according to the common dosage forms prepared.
The preparation technology of Chinese medicine composition of the present invention further is preferably:
Get the Chinese crude drug in the Chinese medicine composition of the present invention, measure Fructus Psoraleae, Herba Epimedii, Rhizoma Polygonati, Rhizoma Drynariae, Fructus Lycii and Radix Achyranthis Bidentatae Six-element medical material, add 10 times of water gagings respectively and decoct, decoct each 1 hour 3 times according to above-mentioned prescription; Merging filtrate, being concentrated into density is the extractum of 1.15-1.25 (60 ℃ of surveys), it is dry that extractum adds calcium lactate, becomes clinical common formulations according to the common dosage forms prepared.
Embodiment
Following examples are used for better setting forth the present invention, only limit to following examples but should not be construed as the present invention.
Embodiment 1
Fructus Psoraleae 240g Herba Epimedii 580g Rhizoma Polygonati 210g Rhizoma Drynariae 580g
Fructus Lycii 500g Radix Achyranthis Bidentatae 500g
Get Fructus Psoraleae, Herba Epimedii, Rhizoma Polygonati, Rhizoma Drynariae, Fructus Lycii and Radix Achyranthis Bidentatae Six-element medical material, add 8 times of water gagings respectively and decoct, decoct each 0.5 hour 4 times; Merging filtrate, being concentrated into density is the extractum of 1.0 (60 ℃ of surveys), and it is dry that extractum adds calcium lactate, processes granule, and packing promptly gets.
Embodiment 2
Fructus Psoraleae 600g Herba Epimedii 210g Rhizoma Polygonati 580g Rhizoma Drynariae 210g
Fructus Lycii 500g Radix Achyranthis Bidentatae 500g
Get Fructus Psoraleae, Herba Epimedii, Rhizoma Polygonati, Rhizoma Drynariae, Fructus Lycii and Radix Achyranthis Bidentatae Six-element medical material, add 10 times of water gagings respectively and decoct, decoct each 1 hour 3 times; Merging filtrate, being concentrated into density is the extractum of 1.5 (60 ℃ of surveys), it is dry that extractum adds calcium lactate, pulverize, capsule charge, packing promptly gets.
Embodiment 3
Fructus Psoraleae 600g Herba Epimedii 580g Rhizoma Polygonati 580g Rhizoma Drynariae 580g
Fructus Lycii 180g Radix Achyranthis Bidentatae 180g
Get Fructus Psoraleae, Herba Epimedii, Rhizoma Polygonati, Rhizoma Drynariae, Fructus Lycii and Radix Achyranthis Bidentatae Six-element medical material, add 12 times of water gagings respectively and decoct, decoct each 3 hours 2 times; Merging filtrate, being concentrated into density is the extractum of 2.0 (60 ℃ of surveys), it is dry that extractum adds calcium lactate, pulverize, tabletting, packing promptly gets.
Embodiment 4
Fructus Psoraleae 600g Herba Epimedii 580g Rhizoma Polygonati 580g Rhizoma Drynariae 580g
Fructus Lycii 500g Radix Achyranthis Bidentatae 500g
Get Fructus Psoraleae, Herba Epimedii, Rhizoma Polygonati, Rhizoma Drynariae, Fructus Lycii and Radix Achyranthis Bidentatae Six-element medical material, add 9 times of water gagings respectively and decoct, decoct each 2 hours 3 times; Merging filtrate, being concentrated into density is the extractum of 1.15 (60 ℃ of surveys), it is dry that extractum adds calcium lactate, pill, packing promptly gets.
Embodiment 5
Fructus Psoraleae 300g Herba Epimedii 300g Rhizoma Polygonati 300g Rhizoma Drynariae 300g
Fructus Lycii 300g Radix Achyranthis Bidentatae 300g
Measure Fructus Psoraleae, Herba Epimedii, Rhizoma Polygonati, Rhizoma Drynariae, Fructus Lycii and Radix Achyranthis Bidentatae Six-element medical material, add 11 times of water gagings respectively and decoct, decoct each 3 hours 2 times; Merging filtrate, being concentrated into density is the extractum of 1.25 (60 ℃ of surveys), and it is dry that extractum adds calcium lactate, and packing promptly gets powder.
Embodiment 6
Fructus Psoraleae 260g Herba Epimedii 230g Rhizoma Polygonati 240g Rhizoma Drynariae 550g
Fructus Lycii 450g Radix Achyranthis Bidentatae 420g
Get Fructus Psoraleae, Herba Epimedii, Rhizoma Polygonati, Rhizoma Drynariae, Fructus Lycii and Radix Achyranthis Bidentatae Six-element medical material, add 10 times of water gagings respectively and decoct, decoct each 2 hours 3 times; Merging filtrate, being concentrated into density is the extractum of 1.20 (60 ℃ of surveys), it is dry that extractum adds calcium lactate, becomes clinical common formulations according to the common dosage forms prepared.
Embodiment 7
Fructus Psoraleae 400g Herba Epimedii 350g Rhizoma Polygonati 350g Rhizoma Drynariae 350g
Fructus Lycii 300g Radix Achyranthis Bidentatae 300g
Measure Fructus Psoraleae, Herba Epimedii, Rhizoma Polygonati, Rhizoma Drynariae, Fructus Lycii and Radix Achyranthis Bidentatae Six-element medical material, add 12 times of water gagings respectively and decoct, decoct each 1.5 hours 2 times; Merging filtrate, being concentrated into density is the extractum of 1.30 (60 ℃ of surveys), it is dry that extractum adds calcium lactate, becomes clinical common formulations according to the common dosage forms prepared.
Embodiment 8 pharmacodynamic experiments
1. experiment material
1.1 laboratory animal
Animal
The SD rat, Mus 12 weeks of age, Shanghai Slac Experimental Animal Co., Ltd., laboratory animal production licence number: SCXK (Shanghai) 2007-0005.
1.2 reagent and medicine
Nilestriol Tablets, Hualian Pharmaceutical Co., Ltd., Shanghai produces, lot number: 110816.Caltrate D tablet, Hui Shi hundred palace pharmaceutical Co. Ltds produce, lot number: 1104118; The extractum of the arbitrary acquisition of embodiment 1-7
The calcium detection kit, Nanjing is built up bio-engineering research and is produced, lot number: 20110613; The Phos detection kit, Nanjing is built up bio-engineering research and is produced, and 20110616; The hydroxyproline detection kit, Nanjing is built up bio-engineering research and is produced, and 20110616; Anti-tartaic acid phosphatase detection kit, Nanjing is built up bio-engineering research and is produced, and 20110616; The alkaline phosphatase enzyme detection kit, Nanjing is built up bio-engineering research and is produced, and 20110528; Calcitonin (CT), PLA General Hospital Science and Technology Development Center puts and exempts from institute, 20110906; Bone Gla protein (BGP), PLA General Hospital Science and Technology Development Center puts and exempts from institute, 20110626; Estradiol (E
2), Beijing North biotechnology research institute, 20110815
1.3 experimental apparatus
Operating theater instruments, surgical thread, Mus plate, hemostatic clamp.
Bone densitometry appearance (Piximus bone densitometer), U.S. General Electronic Lunar company.
2. method
2.1 laboratory animal modeling
Choose 120 of the rats in 12 weeks of Mus age, about body weight 320 ± 20g.With the pentobarbital intraperitoneal anesthesia, get lumbar vertebra both sides otch and get into the abdominal cavity dorsal part, extract bilateral ovaries, hemostatic suture.Wherein blank group rat in kind undergos surgery, and does not just extract ovary.Every the Mus lumbar injection levofloxacin 20mg/kg in operation back injected three days continuously.The removal ovary rat is with low calcium forage feed, and the blank control group rat is to raise with conventional feed.
2.2 divide into groups and administration
After raising a week, the removal ovary rat is divided into 5 groups at random.The heavy dose of group of medicine of the present invention, 4.56g crude drug/kg; Dose groups in the medicine of the present invention, 2.28g crude drug/kg; Medicine small dose group of the present invention, 1.14g crude drug/kg; More than three groups of administrations 6 times weekly.Positive group, Nilestriol Tablets is formulated as suspensoid with 0.5%CMC-Na, gastric infusion 1mg/kg, 1 administration weekly.Simultaneously the Gaierqi D (vitamin D3 and calcium carbonate) tablet is ground, be formulated as suspensoid with 0.5%CMC-Na, gastric infusion 30mg/kg, 6 administrations weekly; Model group and blank control group are given with volume 0.5%CMC-Na (1ml/100g).
2.3 result
After the administration three months, pluck eyeball and get blood, separation of serum-20 ℃ preservation blood biochemical to be measured and hormone index.
2.3.1 influence to rat model bone density (BMD)
Get rat femur, note the protection femoral head, right femur is placed on the lucite box support fixes,, get bone density value (BMD) with the scanning of Piximus bone densitometry appearance.Each organizes data with mean ± standard deviation
expression, carries out statistical analysis with t-test.
Table 1.1 medicine of the present invention is raised the influence
of removal ovary rat bone density to low calcium
##* P＜0.05 is compared with the blank group in P＜0.01, compares with model group.
Embodiment 9 pharmacodynamic experiments
To rat model blood calcitonin, the influence of Bone Gla protein and estradiol
Rat is plucked eyeball and gets blood, and separation of serum adopts corresponding putting to exempt from medicine box, measures calcitonin (CT) in the rat blood serum, Bone Gla protein (BGP) and estradiol (E with SN-682B type γ register
2) content.The result carries out statistical analysis with t-test.
Medicine of the present invention is raised the influence
of removal ovary rat blood hormonal readiness to low calcium
#* P＜0.05 is compared with the blank group in P＜0.05, compares with model group.
Claims (5)
1. one kind is used to treat osteoporotic Chinese medicine composition, it is characterized in that Chinese crude drug composition weight portion ratio is:
Fructus Psoraleae 240-600 Herba Epimedii 210-580 Rhizoma Polygonati 210-580 Rhizoma Drynariae 210-580
Fructus Lycii 180-500 Radix Achyranthis Bidentatae 180-500.
2. Chinese medicine composition as claimed in claim 1 is characterized in that Chinese crude drug composition weight portion ratio is:
Fructus Psoraleae 300-500 Herba Epimedii 280-450 Rhizoma Polygonati 260-480 Rhizoma Drynariae 250-460
Fructus Lycii 220-420 Radix Achyranthis Bidentatae 240-400.
3. Chinese medicine composition as claimed in claim 2 is characterized in that Chinese crude drug composition weight portion ratio is:
Fructus Psoraleae 400 Herba Epimedii 350 Rhizoma Polygonatis 350 Rhizoma Drynariae 350
Fructus Lycii 300 Radix Achyranthis Bidentataes 300.
4. the arbitrary described Chinese medicine composition of claim 1-3, its preparation technology is:
Get the Chinese crude drug in the Chinese medicine composition of the present invention, measure Fructus Psoraleae, Herba Epimedii, Rhizoma Polygonati, Rhizoma Drynariae, Fructus Lycii and Radix Achyranthis Bidentatae Six-element medical material, add 8-12 times of water gaging respectively and decoct, decoct 2-4 time, each 0.5-3 hour according to above-mentioned prescription; Merging filtrate, being concentrated into density is the extractum of 0.8-2.0 (60 ℃ of surveys), it is dry that extractum adds calcium lactate, becomes clinical common formulations according to the common dosage forms prepared.
5. Chinese medicine composition as claimed in claim 4, its preparation technology is:
Get the Chinese crude drug in the Chinese medicine composition of the present invention, measure Fructus Psoraleae, Herba Epimedii, Rhizoma Polygonati, Rhizoma Drynariae, Fructus Lycii and Radix Achyranthis Bidentatae Six-element medical material, add 10 times of water gagings respectively and decoct, decoct each 1 hour 3 times according to above-mentioned prescription; Merging filtrate, being concentrated into density is the extractum of 1.15-1.25 (60 ℃ of surveys), it is dry that extractum adds calcium lactate, becomes clinical common formulations according to the common dosage forms prepared.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210079204XA CN102579817A (en) | 2012-03-23 | 2012-03-23 | Chinese medicine composition with function of treating osteoporosis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210079204XA CN102579817A (en) | 2012-03-23 | 2012-03-23 | Chinese medicine composition with function of treating osteoporosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN102579817A true CN102579817A (en) | 2012-07-18 |
Family
ID=46469418
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201210079204XA Pending CN102579817A (en) | 2012-03-23 | 2012-03-23 | Chinese medicine composition with function of treating osteoporosis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102579817A (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103285233A (en) * | 2013-06-17 | 2013-09-11 | 李伟丽 | Pharmaceutical composition used together with nursing for treating postmenopausal osteoporosis |
| CN103320290A (en) * | 2013-07-02 | 2013-09-25 | 朱玉芳 | Health-care wine and preparation method thereof |
| CN104223306A (en) * | 2014-10-09 | 2014-12-24 | 丁荣吾 | Broad-spectrum and efficient kidney tonifying, stranguria treating and inflammation diminishing functional food and preparation method thereof |
| CN104491414A (en) * | 2014-12-30 | 2015-04-08 | 彭焱 | Traditional Chinese medicine for treating primary osteoporosis and preparation method thereof |
| CN110051771A (en) * | 2019-06-14 | 2019-07-26 | 陕西中医药大学 | A kind of Chinese medicinal tablet and preparation method thereof for treating osteoporosis |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1368375A (en) * | 2001-02-06 | 2002-09-11 | 四川省中药研究所 | Composite medicine for treating osteoporosis |
| CN102008597A (en) * | 2010-12-16 | 2011-04-13 | 西安谦坤商务咨询管理有限公司 | Traditional Chinese medicine composition for treating backache |
| CN102370837A (en) * | 2011-11-10 | 2012-03-14 | 许学猛 | Kidney-invigorating and tendon-reinforcing capsule |
| CN102370170A (en) * | 2011-08-18 | 2012-03-14 | 高益槐 | Health-care food for relieving physical fatigue and preparation method thereof |
-
2012
- 2012-03-23 CN CN201210079204XA patent/CN102579817A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1368375A (en) * | 2001-02-06 | 2002-09-11 | 四川省中药研究所 | Composite medicine for treating osteoporosis |
| CN102008597A (en) * | 2010-12-16 | 2011-04-13 | 西安谦坤商务咨询管理有限公司 | Traditional Chinese medicine composition for treating backache |
| CN102370170A (en) * | 2011-08-18 | 2012-03-14 | 高益槐 | Health-care food for relieving physical fatigue and preparation method thereof |
| CN102370837A (en) * | 2011-11-10 | 2012-03-14 | 许学猛 | Kidney-invigorating and tendon-reinforcing capsule |
Non-Patent Citations (6)
| Title |
|---|
| 《中国骨质疏松杂志》 20060831 高学敏等 "中医预防及改善骨质疏松系列保健食品的研发思路及范例介绍" 第415-423页 1-5 第12卷, 第4期 * |
| 《实用中医内科杂志》 19911231 张大华 "扶脾愈溃汤治疗胃溃疡64例" 第5页 1-5 第5卷, 第3期 * |
| 《成都中医药大学学报》 20071231 李茵 等 "治疗骨质疏松症中药复方的数据挖掘" 第53-55，58页 1-5 第30卷, 第4期 * |
| 张大华: ""扶脾愈溃汤治疗胃溃疡64例"", 《实用中医内科杂志》 * |
| 李茵 等: ""治疗骨质疏松症中药复方的数据挖掘"", 《成都中医药大学学报》 * |
| 高学敏等: ""中医预防及改善骨质疏松系列保健食品的研发思路及范例介绍"", 《中国骨质疏松杂志》 * |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103285233A (en) * | 2013-06-17 | 2013-09-11 | 李伟丽 | Pharmaceutical composition used together with nursing for treating postmenopausal osteoporosis |
| CN103320290A (en) * | 2013-07-02 | 2013-09-25 | 朱玉芳 | Health-care wine and preparation method thereof |
| CN103320290B (en) * | 2013-07-02 | 2015-06-03 | 黑龙江中医药大学 | Health-care wine and preparation method thereof |
| CN104223306A (en) * | 2014-10-09 | 2014-12-24 | 丁荣吾 | Broad-spectrum and efficient kidney tonifying, stranguria treating and inflammation diminishing functional food and preparation method thereof |
| CN104491414A (en) * | 2014-12-30 | 2015-04-08 | 彭焱 | Traditional Chinese medicine for treating primary osteoporosis and preparation method thereof |
| CN110051771A (en) * | 2019-06-14 | 2019-07-26 | 陕西中医药大学 | A kind of Chinese medicinal tablet and preparation method thereof for treating osteoporosis |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101284073B (en) | Combination medicine for curing the hoary hair | |
| CN102579817A (en) | Chinese medicine composition with function of treating osteoporosis | |
| CN104547750A (en) | Traditional Chinese medicine composition for treating senile osteoporosis | |
| CN102755593B (en) | Traditional Chinese medicine composition for treating qi goiter and preparation method thereof | |
| CN104922613A (en) | Medicine composite for treating sterility and preparation method thereof | |
| CN102727711B (en) | Traditional Chinese medicine used for treating chronic fatigue syndrome | |
| CN102671178B (en) | Preparation method of Chinese medicinal composition for treating nephrotic syndrome and uremia and application thereof | |
| CN104225417A (en) | Traditional Chinese medicine composition with function of assisting improvement of memory and preparation method thereof | |
| CN1669577A (en) | Chinese medicine preparation for treating osteoporosis and fracture and preparation process thereof | |
| CN101041007A (en) | Kidney invigorating medicine for improving sperm generation and its prepn method | |
| CN101095768A (en) | Chinese traditional medicine capsule for treating primary hypertension for persons in middle and old age | |
| CN104524524B (en) | Medicine treating osteoporosis and preparing method | |
| CN106511549A (en) | Traditional Chinese medicine composition containing millettia specisoa and preparation method of traditional Chinese medicine composition | |
| CN106361981A (en) | Traditional Chinese medicine with effects of nourishing yin and strengthening yang | |
| CN106361856A (en) | Anti-osteoporosis traditional Chinese medicinal composition and preparation method thereof | |
| CN103191315B (en) | Traditional Chinese medicine for treating postmenopausal osteoporosis | |
| CN104906526A (en) | Chinese medicine preparation for premature ovarian failure and preparation method of Chinese medicine preparation | |
| CN105213905A (en) | A kind of Chinese medicine composition and application thereof preventing and treating postmenopausal osteoporosis | |
| CN105343761A (en) | Traditional Chinese medicine composition for treating myocardial infarction and preparation method thereof | |
| CN112755134B (en) | Plaster for treating hyperosteogeny and preparation method thereof | |
| CN1193784C (en) | Chinese medicine for treating infantile uterus | |
| CN105497420A (en) | Medicine for treating primary osteoporosis through kidney-tonifying, spleen-strengthening and blood-stasis-removing method | |
| CN102641472B (en) | Chinese herbal preparation for curing osteoporosis | |
| CN105412633A (en) | Traditional Chinese medicinal composition for treating recurrent aphthous ulcer | |
| CN105327316A (en) | Medicament for treating anterior hypopituitarism |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20120718 |